Net Income of $3.4 Million Improving from a Net Loss of $5.5 Million Adjusted EBITDA increased to $9.4 Million, up 269% YoY Delivered 1H Revenue of $277 million, a 24% YoY increase EV Premiums increased 31% YoY to $916 million NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — SunCar Technology Group Inc. (the “Company” or “SunCar”) (NASDAQ: SDA), an innovative leader in AI-powered auto insurance and auto services, today announced financial results for the six months ended June 30, 2026. “SunCar had an excellent first half generating $3.4 million in net income, a substantial $8.9 million improvement from a $5.5 million net loss the first half of 2025,” said Zaichang Ye, Chairman and CEO of SunCar. “Our top-line growth of 24% demonstrated that SunCar can maintain strong revenue growth while also growing profits....

COLUMBUS, Ohio, Sept. 22, 2026 (GLOBE NEWSWIRE) — Worthington Enterprises Inc. (NYSE: WOR), a designer and manufacturer of market-leading products and solutions for building, trade and specialty applications, today reported results for its fiscal 2027 first quarter ended August 31, 2026. Recent Developments and First Quarter Highlights (all comparisons to the first quarter of fiscal 2026)Net sales were $343.9 million, an increase of $40.2 million, or 13%, including 6% from recent acquisitions and 7% from organic growth. Net earnings increased 22% to $42.6 million, while adjusted net earnings increased 3% to $40.1 million and adjusted EBITDA grew 10% to $74.0 million. Earnings per share on a fully diluted basis (“EPS – diluted”) improved to $0.87 from $0.70 per share, while adjusted EPS – diluted increased to $0.82 per share compared...

EXOR PUBLISHES HALF-YEAR REPORT AND ANNOUNCES €500 MILLION SHARE BUYBACKPortfolio simplification continuedIveco Group completed the sale of its defence business to Leonardo, Tata Motors launched its tender offer for Iveco Group, with closing expected in November 2026 Exor also completed the divestments in GEDI, Lifenet and NUO and reached an agreement to sell its stake in Welltec. The Welltec deal will return a MOIC of approximately 2.4x and bring Exor’s deployable cash to around €4 billionNAV per share declined 3.9% in the first half of 2026, compared with an 11.8% increase in the MSCI World Index Exor intends to launch a share buyback program of up to €500 million, to be executed on the market until its next financial results in March 2027“The reshaping of our portfolio has continued. We are pleased with this year’s...

Record Bookings in H1 2026Sharp rise in bookings: +112% to €5.16M in new annual recurring subscriptions (ARR), 20% above the amount signed for full-year 2025 AI-native products: €1.02M in new ARR signed, representing 33% of the 2026 Q2 totalMore Than 71% of Revenue Generated Outside FranceRevenue up sharply: +21%, including +26% for subscriptions at constant currency (+19% and +23% as reported)Double-Digit Growth in ProfitabilityEBIT: €5.7M, up 22% and 33% like-for-like (20.7% of revenue, versus 15.7% in H1 2025) Net income: €4.7M, up 15% Gross cash: €19.9M as of June 30, 2026 Sovereign AI, from GPUs to the natural-language interfaceSidetrade, an AI-native company dedicated to Order-to-Cash, reported strong growth in both its business and its profitability in the first half of 2026. First-half revenue reached €34.8 million,...

Ad hoc announcement pursuant to Art. 53 LR MILAN, Italy and MORRISTOWN, N. J., Sept. 22, 2026 (GLOBE NEWSWIRE) — Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the first half of 2026, and provided a corporate update. Highlights H1 2026: EvenamideENIGMA-TRS 1: Screening for enrollment completed post-period in September. Target enrollment of at least 600 patients expected around mid-October, Topline 12-week results in Q1 2027 ENIGMA-TRS 2: Following a constructive Type A meeting with the FDA in July, Newron expects US enrollment to resume in the near future. Ongoing enrollment outside the US IP: European...

MEMPHIS, Tenn., Sept. 22, 2026 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO) today reported net sales of $6.6 billion for its fourth quarter (16 weeks) ended August 29, 2026, an increase of 5.6% from the fourth quarter of fiscal 2025 (16 weeks). Same store sales, or sales for our domestic and international stores open at least one year, are as follows:                     Constant Currency       Constant Currency  16 Weeks   16 Weeks*   52 Weeks   52 Weeks*               Domestic 1.6 %   1.6 %   3.3 %   3.3 %International 10.7 %   1.3 %   13.5 %   2.2 %Total Company 2.7 %   1.5 %   4.5 %   3.2 %* Excludes impacts from fluctuations of foreign exchange rates.          For the quarter, gross profit, as a percentage of sales, was 53.3%, an increase of 182 basis points versus the prior year. The increase in...

BEIJING, Sept. 22, 2026 (GLOBE NEWSWIRE) — Here Group Limited (NASDAQ: HERE) (“Here” or the “Company”), an IP1-based pop toy company dedicated to creating beloved collectibles and trend-defining experiences, today announced its unaudited financial results for the fourth quarter and full year of the fiscal year ended June 30, 2026 (the “fourth quarter of FY 2026”, which refers to the quarter from April 1, 2026 to June 30, 2026, and “FY 2026”, which refers to the year from July 1, 2025 to June 30, 2026). Highlights for the Fourth Quarter of FY 20262Revenues for the fourth quarter of FY 2026 were RMB127.7 million (US$18.8 million), representing a decrease of 22.5% from the third quarter of the fiscal year ended June 30, 2026 (the “third quarter of FY 2026”), and representing an increase of 94.1% from the fourth quarter of the fiscal...

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain. DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2026 The Board of DXS International plc (AQSE: DXSP)(“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2026. Financial HighlightsProfit of £61,839 (2025: loss of £94,750). Revenue decreased...

ABC arbitrage HY 2026 Consolidated Results¹: €26.0 m (+47%) Annualised ROE 2026: 27.4% | EPS HY 2026: €0.44The Board of Directors of ABC arbitrage, presided by the Chairman Dominique Ceolin, met on September 17, 2026 to approve the consolidated financial statements for the first semester 2026¹. Key financial data are as follows:In millions of euros June 30, 2026 IFRS June 30, 2025 IFRS Var % Dec. 31, 2025 IFRSCurrent operating income €51.0 m €36.5 m 40% €59.7 mNet income €26.0 m €17.7 m 47% €25.1 mEarnings per share (EPS) €0.44 €0.30 47% €0.42Return on equity (ROE) 27.4 % 20.3 % 35% 14.8 %Equity €189.2 m €174.4 m 8% €169.6 mContext – In the first half of 2026, the progressive increase in volatility culminated in a significant period of stress, without, however, reaching the levels recorded in April 2025. Over the...

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision Litigation with GSK and Tesaro: trial held in July; post-trial hearing scheduled for October 20, 2026, with a judgement anticipated in Q4 2026 or Q1 2027SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported...